Scott Dahlbeck
Fondatore presso KIROMIC BIOPHARMA, INC.
Patrimonio netto: 182 186 $ in data 31/05/2024
Profilo
Scott Dahlbeck is the founder and currently holds the position of Chief of Staff at Kiromic Biopharma, Inc., a company he founded in 2006.
He is also the founder and currently holds the position of President & Chief Medical Officer at Kiromic, Inc., a company he founded in 2013.
Dr. Dahlbeck has a doctorate degree from the University of Nebraska Medical Center and The University of Texas Health Science Center at Houston.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
KIROMIC BIOPHARMA, INC.
3.69% | 15/05/2024 | 56 933 ( 3.69% ) | 182 186 $ | 31/05/2024 |
Posizioni attive di Scott Dahlbeck
| Società | Posizione | Inizio |
|---|---|---|
| KIROMIC BIOPHARMA, INC. | Fondatore | 06/08/2006 |
Kiromic, Inc.
 Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Fondatore | 01/01/2013 |
Formazione di Scott Dahlbeck
| The University of Texas Health Science Center at Houston | Doctorate Degree |
| University of Nebraska Medical Center | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Kiromic, Inc.
Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Health Services |
- Borsa valori
- Insiders
- Scott Dahlbeck
